| pubmed-article:17616938 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17616938 | lifeskim:mentions | umls-concept:C0279702 | lld:lifeskim |
| pubmed-article:17616938 | lifeskim:mentions | umls-concept:C0003693 | lld:lifeskim |
| pubmed-article:17616938 | lifeskim:mentions | umls-concept:C0205217 | lld:lifeskim |
| pubmed-article:17616938 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:17616938 | lifeskim:mentions | umls-concept:C0205214 | lld:lifeskim |
| pubmed-article:17616938 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:17616938 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:17616938 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:17616938 | pubmed:dateCreated | 2007-7-9 | lld:pubmed |
| pubmed-article:17616938 | pubmed:abstractText | The clinical behaviour of Clear Cell Renal Cell Carcinoma (CC-RCC) is often unpredictable. To fully understand the signaling pathways involved in CC-RCC development, we examined whether the 5-Lipoxygenase (5-LO), which catalyzes the biosynthesis of proinflammatory leukotrienes, is involved in renal tumorigenesis. By analyzing 46 snap-frozen primary renal cell carcinomas and their corresponding normal renal cortex biopsies, 5-LO protein levels were found to be significantly increased in the majority of CC-RCCs (P<0.001). Quantitative 5-LO mRNA expression analysis revealed up to 3-fold increased expression in the tumor tissues. There was no association between 5-LO and gender, grade or vein invasion. In contrast, increased 5-LO protein and mRNA correlated with large tumor size (>4 cm) and age of patients (P<0.001). 5-LO was frequently overexpressed in von Hippel-Lindau protein (pVHL)-reduced tumors and in Vascular Endothelial Growth Factor (VEGF)-positive tumors, which represent two frequent alterations in CC-RCC. Cell culture experiments demonstrated that VEGF expression was strongly inducible by 5-LO metabolites in RCC cell lines. The loss of pVHL expression led to high basal 5-LO and VEGF expression, which were markedly reduced by transfection with 5-LO small interfering RNA (siRNA). These results suggest that 5-LO up-regulation is an important step in renal cancer progression. | lld:pubmed |
| pubmed-article:17616938 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17616938 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17616938 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17616938 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17616938 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17616938 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17616938 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17616938 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17616938 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17616938 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17616938 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17616938 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:17616938 | pubmed:issn | 1699-5848 | lld:pubmed |
| pubmed-article:17616938 | pubmed:author | pubmed-author:CatalanoAA | lld:pubmed |
| pubmed-article:17616938 | pubmed:author | pubmed-author:MuzzonigroGG | lld:pubmed |
| pubmed-article:17616938 | pubmed:author | pubmed-author:MilanesiCC | lld:pubmed |
| pubmed-article:17616938 | pubmed:author | pubmed-author:ProcopioAA | lld:pubmed |
| pubmed-article:17616938 | pubmed:author | pubmed-author:BonfigliA RAR | lld:pubmed |
| pubmed-article:17616938 | pubmed:author | pubmed-author:MennaCC | lld:pubmed |
| pubmed-article:17616938 | pubmed:author | pubmed-author:FaronatoMM | lld:pubmed |
| pubmed-article:17616938 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:17616938 | pubmed:volume | 22 | lld:pubmed |
| pubmed-article:17616938 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17616938 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17616938 | pubmed:pagination | 1109-18 | lld:pubmed |
| pubmed-article:17616938 | pubmed:meshHeading | pubmed-meshheading:17616938... | lld:pubmed |
| pubmed-article:17616938 | pubmed:meshHeading | pubmed-meshheading:17616938... | lld:pubmed |
| pubmed-article:17616938 | pubmed:meshHeading | pubmed-meshheading:17616938... | lld:pubmed |
| pubmed-article:17616938 | pubmed:meshHeading | pubmed-meshheading:17616938... | lld:pubmed |
| pubmed-article:17616938 | pubmed:meshHeading | pubmed-meshheading:17616938... | lld:pubmed |
| pubmed-article:17616938 | pubmed:meshHeading | pubmed-meshheading:17616938... | lld:pubmed |
| pubmed-article:17616938 | pubmed:meshHeading | pubmed-meshheading:17616938... | lld:pubmed |
| pubmed-article:17616938 | pubmed:meshHeading | pubmed-meshheading:17616938... | lld:pubmed |
| pubmed-article:17616938 | pubmed:meshHeading | pubmed-meshheading:17616938... | lld:pubmed |
| pubmed-article:17616938 | pubmed:meshHeading | pubmed-meshheading:17616938... | lld:pubmed |
| pubmed-article:17616938 | pubmed:meshHeading | pubmed-meshheading:17616938... | lld:pubmed |
| pubmed-article:17616938 | pubmed:meshHeading | pubmed-meshheading:17616938... | lld:pubmed |
| pubmed-article:17616938 | pubmed:meshHeading | pubmed-meshheading:17616938... | lld:pubmed |
| pubmed-article:17616938 | pubmed:meshHeading | pubmed-meshheading:17616938... | lld:pubmed |
| pubmed-article:17616938 | pubmed:meshHeading | pubmed-meshheading:17616938... | lld:pubmed |
| pubmed-article:17616938 | pubmed:meshHeading | pubmed-meshheading:17616938... | lld:pubmed |
| pubmed-article:17616938 | pubmed:meshHeading | pubmed-meshheading:17616938... | lld:pubmed |
| pubmed-article:17616938 | pubmed:meshHeading | pubmed-meshheading:17616938... | lld:pubmed |
| pubmed-article:17616938 | pubmed:meshHeading | pubmed-meshheading:17616938... | lld:pubmed |
| pubmed-article:17616938 | pubmed:meshHeading | pubmed-meshheading:17616938... | lld:pubmed |
| pubmed-article:17616938 | pubmed:meshHeading | pubmed-meshheading:17616938... | lld:pubmed |
| pubmed-article:17616938 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17616938 | pubmed:articleTitle | Increased expression of 5-lipoxygenase is common in clear cell renal cell carcinoma. | lld:pubmed |
| pubmed-article:17616938 | pubmed:affiliation | Department of Molecular Pathology and Innovative Therapies, Polytechnic University of Marche, Ancona, Italy. | lld:pubmed |
| pubmed-article:17616938 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17616938 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:240 | entrezgene:pubmed | pubmed-article:17616938 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:17616938 | lld:entrezgene |
| lhgdn:association:41892 | lhgdn:found_in | pubmed-article:17616938 | lld:lhgdn |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17616938 | lld:pubmed |
